The U.S. health regulator has added its strictest warning to the labels of drugs from Pfizer (PFE.N), Eli Lilly (LLY.N) and AbbVie (ABBV.N) belonging to a class of anti-inflammatory treatments called JAK inhibitors, citing risk of serious health issues and death in patients 50 and over, the drugmakers said on Friday.